In Pharmaceutical industry, most companies in Brazil have been based in Rio de Janeiro and São Paulo for a long time. In 2019, the situation was that, due to the tax advantages offered in states like Pernambuco, Goiás and Minas Gerais, companies were leaving RJ and SP, and going to these states. At the time, the more than 110 companies associated with Sinfar-RJ fell to just 49. Rio de Janeiro, at this time, represented the most expensive state for pharmaceutical production, with its ICMS at 20%. Even in 2019, the Rio de Janeiro industrial park had revenues of almost R $8 billion and an 11% share in the Brazilian pharmaceutical market. In the Jacarepaguá neighborhood, there are several pharmaceutical industries, such as GSK, Roche, Merck, Servier and Abbott. In 2017, Brazil was considered the sixth largest pharmaceutical market in the world. Drug sales in pharmacies reached around R $57 billion (US $17.79 billion) in the country. The pharmaceutical market in Brazil had 241 laboratories regularized and authorized for the sale of medicines. Of these, the majority (60%) have national capital. Multinational companies held about 52.44% of the market, with 34.75% in marketed packaging. Brazilian laboratories represent 47.56% of the market in sales and 65.25% in boxes sold. In the distribution of drug sales by state, São Paulo occupied the first position: the São Paulo drug industry had a turnover of R $53.3 billion, 76.8% of total sales across the country. Just behind came Rio de Janeiro, which had revenues of approximately R $7.8 billion. The pharmaceutical industry's exports reached US $1.247 billion in 2017. The companies that most profited from the sale of medicines in the country in 2015 were EMS, Hypermarcas (NeoQuímica), Sanofi (Medley), Novartis, Aché, Eurofarma, Takeda, Bayer, Pfizer and GSK.